featured
NALIRIFOX vs Nab-Paclitaxel and Gemcitabine for Treatment-Naïve Metastatic Pancreatic Ductal Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
Lancet 2023 Sep 11;[EPub Ahead of Print], ZA Wainberg, D Melisi, T Macarulla, R Pazo Cid, SR Chandana, C De La Fouchardière, A Dean, I Kiss, WJ Lee, TO Goetze, E Van Cutsem, AS Paulson, T Bekaii-Saab, S Pant, RA Hubner, Z Xiao, H Chen, F Benzaghou, EM O'ReillyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.